These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9885821)

  • 1. A mouse model for learning and memory defects associated with neurofibromatosis type I.
    Silva AJ; Elgersma Y; Friedman E; Stern J; Kogan J
    Pathol Biol (Paris); 1998 Nov; 46(9):697-8. PubMed ID: 9885821
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.
    Costa RM; Federov NB; Kogan JH; Murphy GG; Stern J; Ohno M; Kucherlapati R; Jacks T; Silva AJ
    Nature; 2002 Jan; 415(6871):526-30. PubMed ID: 11793011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
    Li W; Cui Y; Kushner SA; Brown RA; Jentsch JD; Frankland PW; Cannon TD; Silva AJ
    Curr Biol; 2005 Nov; 15(21):1961-7. PubMed ID: 16271875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contributions of research to the understanding learning disorders in neurofibromatosis type 1].
    Chaix Y
    Arch Pediatr; 2004 Jun; 11(6):548-9. PubMed ID: 15158828
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1.
    Ullrich NJ; Ayr L; Leaffer E; Irons MB; Rey-Casserly C
    J Child Neurol; 2010 Oct; 25(10):1195-202. PubMed ID: 20139412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromin, a tumor suppressor in the nervous system.
    Zhu Y; Parada LF
    Exp Cell Res; 2001 Mar; 264(1):19-28. PubMed ID: 11237520
    [No Abstract]   [Full Text] [Related]  

  • 7. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
    Parada LF; Kwon CH; Zhu Y
    Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.
    Costa RM; Silva AJ
    J Child Neurol; 2002 Aug; 17(8):622-6; discussion 627-9, 646-51. PubMed ID: 12403561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
    Xu J; Ismat FA; Wang T; Yang J; Epstein JA
    Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.
    Pedersen WA; McMillan PJ; Kulstad JJ; Leverenz JB; Craft S; Haynatzki GR
    Exp Neurol; 2006 Jun; 199(2):265-73. PubMed ID: 16515786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease.
    Ambrée O; Richter H; Sachser N; Lewejohann L; Dere E; de Souza Silva MA; Herring A; Keyvani K; Paulus W; Schäbitz WR
    Neurobiol Aging; 2009 Aug; 30(8):1192-204. PubMed ID: 18079024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific learning and cognitive deficits in neurofibromatosis type 1].
    Mahajnah M; Zimmerman S; Weitz R
    Harefuah; 2001 Apr; 140(4):334-6. PubMed ID: 11303400
    [No Abstract]   [Full Text] [Related]  

  • 14. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
    Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
    Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 1.
    McLaughlin ME; Jacks T
    Methods Mol Biol; 2003; 222():223-37. PubMed ID: 12710690
    [No Abstract]   [Full Text] [Related]  

  • 16. Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model.
    Saito H; Yoshida T; Yamazaki H; Suzuki N
    Oncogene; 2007 Jul; 26(32):4714-9. PubMed ID: 17237809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral phenotype of neurofibromatosis, type 1.
    Kayl AE; Moore BD
    Ment Retard Dev Disabil Res Rev; 2000; 6(2):117-24. PubMed ID: 10899804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [P21ras--a central cross-road on intracellular signalling].
    Levy O; Ramot Y; Rapoport M
    Harefuah; 1997 Oct; 133(7-8):304-8. PubMed ID: 9418364
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurofibromatosis type 1: II. Answers from animal models.
    Lakkis MM; Tennekoon GI
    J Neurosci Res; 2001 Aug; 65(3):191-4. PubMed ID: 11494353
    [No Abstract]   [Full Text] [Related]  

  • 20. Age-related changes in visual acuity, learning and memory in C57BL/6J and DBA/2J mice.
    Wong AA; Brown RE
    Neurobiol Aging; 2007 Oct; 28(10):1577-93. PubMed ID: 17010477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.